002166 莱茵生物
已收盘 10-30 15:00:00
资讯
新帖
简况
莱茵生物（002166）2026年三季报简析：净利润同比下降10.29%，应收账款上升
证券之星 · 10-31 07:43
莱茵生物（002166）2026年三季报简析：净利润同比下降10.29%，应收账款上升
莱茵生物：公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑
证券之星 · 10-30 11:36
莱茵生物：公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑
股市必读：莱茵生物三季报 - 第三季度单季净利润同比下降79.52%
证券之星 · 10-30 05:32
股市必读：莱茵生物三季报 - 第三季度单季净利润同比下降79.52%
图解莱茵生物三季报：第三季度单季净利润同比下降79.52%
证券之星 · 10-29
图解莱茵生物三季报：第三季度单季净利润同比下降79.52%
莱茵生物：核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物
证券之星 · 10-23
莱茵生物：核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物
莱茵生物（002166）10月9日主力资金净买入151.10万元
证券之星 · 10-12
莱茵生物（002166）10月9日主力资金净买入151.10万元
公司问答丨莱茵生物：公司甜菊糖苷RM2的国内新食品添加剂认证处于审核阶段
格隆汇 · 09-15
公司问答丨莱茵生物：公司甜菊糖苷RM2的国内新食品添加剂认证处于审核阶段
莱茵生物：甜菊糖苷RM2已通过美国FDA GRAS认证
证券之星 · 09-15
莱茵生物：甜菊糖苷RM2已通过美国FDA GRAS认证
9月14日增减持汇总：莱茵生物等8股拟减持，当日暂无A股上市公司拟增持（表）
新浪证券 · 09-14
9月14日增减持汇总：莱茵生物等8股拟减持，当日暂无A股上市公司拟增持（表）
莱茵生物：坚持以自主研发为核心
证券之星 · 09-10
莱茵生物：坚持以自主研发为核心
莱茵生物：公司作为全球天然甜味剂的主要供应商之一
证券之星 · 09-10
莱茵生物：公司作为全球天然甜味剂的主要供应商之一
莱茵生物：甜菊糖苷RM2及生物多糖认证均处于审核阶段
证券之星 · 09-10
莱茵生物：甜菊糖苷RM2及生物多糖认证均处于审核阶段
莱茵生物：9月1日接受机构调研，包括知名机构正圆投资的多家机构参与
证券之星 · 09-07
莱茵生物：9月1日接受机构调研，包括知名机构正圆投资的多家机构参与
莱茵生物（002166）披露2026年半年度报告，8月31日股价下跌1.59%
证券之星 · 08-31
莱茵生物（002166）披露2026年半年度报告，8月31日股价下跌1.59%
莱茵生物（002166）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 08-30
莱茵生物（002166）2026年中报简析：营收净利润同比双双增长，应收账款上升
莱茵生物(002166)6月30日股东户数3.7万户，较上期减少5.16%
证券之星 · 08-29
莱茵生物(002166)6月30日股东户数3.7万户，较上期减少5.16%
图解莱茵生物中报：第二季度单季净利润同比增长91.75%
证券之星 · 08-29
图解莱茵生物中报：第二季度单季净利润同比增长91.75%
莱茵生物董秘罗华阳荣获第十二届金麒麟·金牌董秘荣誉
新浪财经 · 08-10
莱茵生物董秘罗华阳荣获第十二届金麒麟·金牌董秘荣誉
股市必读：莱茵生物（002166）7月31日董秘有最新回复
证券之星 · 08-03
股市必读：莱茵生物（002166）7月31日董秘有最新回复
莱茵生物：与海内外众多品牌客户建立稳定合作
证券之星 · 07-23
莱茵生物：与海内外众多品牌客户建立稳定合作
加载更多
公司概况
公司名称：
桂林莱茵生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2007-09-13
主营业务：
桂林莱茵生物科技股份有限公司的主营业务是天然健康功能性成分的研发与生产。公司的主要产品是罗汉果提取物、甜叶菊提取物、茶叶提取物及其他植物提取物、甜菊糖苷RM系列产品、左旋β-半乳葡聚糖。
发行价格：
9.89
{"stockData":{"symbol":"002166","market":"SZ","secType":"STK","nameCN":"莱茵生物","latestPrice":5.91,"timestamp":1793343807000,"preClose":6.05,"halted":0,"volume":9607477,"delay":0,"changeRate":-0.0231,"floatShares":739000000,"shares":742000000,"eps":0.1833,"marketStatus":"已收盘","change":-0.14,"latestTime":"10-30 15:00:00","open":6,"high":6.17,"low":5.9,"amount":57705100,"amplitude":0.0446,"askPrice":5.92,"askSize":369,"bidPrice":5.91,"bidSize":3843,"shortable":0,"etf":0,"ttmEps":0.1833,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":6.05,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":6.66,"lowLimit":5.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":741609425,"isCdr":false,"pbRate":1.44,"roa":"--","peRate":32.242226,"roe":"2.01%","epsLYR":0.1945,"committee":0.765548,"marketValue":4383000000,"turnoverRate":0.013,"status":1,"floatMarketCap":4365000000},"requestUrl":"/m/hq/s/002166","defaultTab":"news","newsList":[{"id":"2679225234","title":"莱茵生物（002166）2026年三季报简析：净利润同比下降10.29%，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2679225234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679225234?lang=zh_cn&edition=full","pubTime":"2026-10-31 07:43","pubTimestamp":1793403817,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期莱茵生物发布2026年三季报。截至本报告期末，公司营业总收入12.25亿元，同比下降3.74%，归母净利润6315.41万元，同比下降10.29%。按单季度数据看，第三季度营业总收入3.51亿元，同比下降19.31%，第三季度归母净利润661.1万元，同比下降79.52%。本报告期莱茵生物应收账款上升，应收账款同比增幅达35.99%。去年的净利率为7.48%，算上全部成本后，公司产品或服务的附加值一般。本文数据来源于莱茵生物2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100016789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679250484","title":"莱茵生物：公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2679250484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679250484?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:36","pubTimestamp":1793331406,"startTime":"0","endTime":"0","summary":"证券之星消息，莱茵生物(002166)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：造成公司三季报业绩下降10%是公司的第三季度的主营收入同比少了8400万，请问第三季度主营收入下降是什么原因？莱茵生物回复：您好，公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑。公司天然甜味剂业务整体经营稳健。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000024633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679378712","title":"股市必读：莱茵生物三季报 - 第三季度单季净利润同比下降79.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679378712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679378712?lang=zh_cn&edition=full","pubTime":"2026-10-30 05:32","pubTimestamp":1793309573,"startTime":"0","endTime":"0","summary":"截至2026年10月29日收盘，莱茵生物报收于6.05元，下跌5.47%，换手率1.57%，成交量11.61万手，成交额7103.7万元。业绩披露要点财务报告2026年前三季度主营收入12.25亿元，同比下降3.74%；归母净利润6315.41万元，同比下降10.29%；扣非净利润4354.52万元，同比下降29.14%。公司公告汇总2026年三季度报告2026年第三季度营业收入为3.51亿元，同比下降19.31%；归母净利润为661.1万元，同比下降79.52%。经营活动产生的现金流量净额为4.79亿元，同比增长38.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000007478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679141578","title":"图解莱茵生物三季报：第三季度单季净利润同比下降79.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679141578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679141578?lang=zh_cn&edition=full","pubTime":"2026-10-29 03:44","pubTimestamp":1793216663,"startTime":"0","endTime":"0","summary":"证券之星消息，莱茵生物2026年三季报显示，前三季度公司主营收入12.25亿元，同比下降3.74%；归母净利润6315.41万元，同比下降10.29%；扣非净利润4354.52万元，同比下降29.14%；其中2026年第三季度，公司单季度主营收入3.51亿元，同比下降19.31%；单季度归母净利润661.1万元，同比下降79.52%；单季度扣非净利润-164.64万元，同比下降105.93%；负债率35.22%，投资收益226.15万元，财务费用3120.92万元，毛利率24.18%。财报数据概要请见下图:本文数据来源于莱茵生物2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900003862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677913691","title":"莱茵生物：核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物","url":"https://stock-news.laohu8.com/highlight/detail?id=2677913691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677913691?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:39","pubTimestamp":1792715949,"startTime":"0","endTime":"0","summary":"公司核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物，不同纯度的产品甜度可达蔗糖几十倍至百倍以上，产品热量低，无代谢负担。莱茵生物长期深耕功能性健康成分赛道，以向消费者提供健康产品、赋能大健康产业为长期目标，为全球食品、饮料、调味品等领域客户提供天然减糖原料及定制化配方服务，满足大众控糖的健康需求，助力推动公共健康事业发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300008352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0168","BK0028","002166","BK0239","BK0174"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674847343","title":"莱茵生物（002166）10月9日主力资金净买入151.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674847343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674847343?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:07","pubTimestamp":1791767244,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月9日收盘，莱茵生物报收于7.3元，上涨4.89%，换手率3.31%，成交量24.41万手，成交额1.75亿元。近5日资金流向一览见下表：莱茵生物融资融券信息显示，融资方面，当日融资买入3423.58万元，融资偿还1088.58万元，融资净买入2335.0万元，连续3日净买入累计3775.0万元。莱茵生物主营业务：天然健康产品的生产经营业务,持续专注植物功能性成分提取领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200002899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0028","BK0239","BK0174","BK0046","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617302","title":"公司问答丨莱茵生物：公司甜菊糖苷RM2的国内新食品添加剂认证处于审核阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617302","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617302?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:54","pubTimestamp":1789458841,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0046","BK0174","002166","BK0168","159151","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667568692","title":"莱茵生物：甜菊糖苷RM2已通过美国FDA GRAS认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2667568692","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667568692?lang=zh_cn&edition=full","pubTime":"2026-09-15 08:45","pubTimestamp":1789433111,"startTime":"0","endTime":"0","summary":"证券之星消息，莱茵生物09月14日在投资者关系平台上答复投资者关心的问题。莱茵生物回复：您好，公司甜菊糖苷RM2已通过美国FDA GRAS认证，具备海外销售资质；国内新食品添加剂认证处于审核阶段。目前，公司合成生物业务已完成产能、研发、销售全链条布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500006637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","BK0174","BK0046","BK0239","BK0168","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661424","title":"9月14日增减持汇总：莱茵生物等8股拟减持，当日暂无A股上市公司拟增持（表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661424","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667661424?lang=zh_cn&edition=full","pubTime":"2026-09-14 21:52","pubTimestamp":1789393920,"startTime":"0","endTime":"0","summary":"9月14日盘后，据不完全统计，包括美年健康、誉衡药业、莱茵生物、奥浦迈、江河集团、东来技术、山东玻纤、楚天龙等在内的8家A股上市公司披露拟减持情况，当日暂无A股上市公司披露拟增持情况。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-inirveas7272654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0168","02827","02846","BK0028","03130","002166","BK0174","82846","BK0239","03188","399300","83188","BK1147","83130","07233","159982","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666556429","title":"莱茵生物：坚持以自主研发为核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666556429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666556429?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:54","pubTimestamp":1789001654,"startTime":"0","endTime":"0","summary":"证券之星消息，莱茵生物09月09日在投资者关系平台上答复投资者关心的问题。我们在上海搭建了复合型研发平台，核心团队由多名博士牵头，研发布局覆盖食品饮料配方应用、日化应用开发以及合成生物技术攻关三大方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0046","BK0168","BK0174","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666055649","title":"莱茵生物：公司作为全球天然甜味剂的主要供应商之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2666055649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666055649?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:54","pubTimestamp":1789001654,"startTime":"0","endTime":"0","summary":"证券之星消息，莱茵生物(002166)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，董秘，绿可乐自2026年5月上市以来，累计销量突破60万箱、1440万瓶，年度目标从50万箱直接上调到200万箱，是原计划的四倍，网上流传甜菊糖苷供应商为莱茵生物，能否证实？莱茵生物回复：您好，公司作为全球天然甜味剂的主要供应商之一，近年来持续开拓下游应用市场，与海内外众多品牌客户建立稳定合作，覆盖食品、饮料、调味品、化妆品等赛道。关于下游客户合作情况，您可参考品牌官方公开信息，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0168","BK0174","BK0239","BK0046","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666556425","title":"莱茵生物：甜菊糖苷RM2及生物多糖认证均处于审核阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666556425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666556425?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:54","pubTimestamp":1789001653,"startTime":"0","endTime":"0","summary":"证券之星消息，莱茵生物(002166)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司合成生物业务的甜菊糖苷RM2和生物多糖认证审批是否已中止或终止，久未有消息了？莱茵生物回复：您好， 公司甜菊糖苷RM2的国内新食品添加剂认证、左旋β-半乳葡聚糖的国内新食品原料及美国FDA GRAS认证均处于审核阶段，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","002166","BK0046","BK0174","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665115363","title":"莱茵生物：9月1日接受机构调研，包括知名机构正圆投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665115363","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665115363?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:33","pubTimestamp":1788773618,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月1日莱茵生物发布公告称公司于2026年9月1日接受机构调研，中信建投杨骥 高畅、源乘投资曾尚、衍复投资张道武、中泰证券田海川、华夏基金胡慧婷 李柄桦、宏利基金刘硕、红土创新基金张豪、民生基金董博、国海富兰克林基金张瑞、金元顺安基金侯斌、正圆投资冯荃晴、睿亿投资吕乐艺参与。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002166","BK0168","BK0174","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070952","title":"莱茵生物（002166）披露2026年半年度报告，8月31日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070952","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663070952?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:31","pubTimestamp":1788175866,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，莱茵生物报收于6.81元，较前一交易日下跌1.59%，最新总市值为50.5亿元。该股当日开盘6.95元，最高6.95元，最低6.76元，成交额达6606.44万元，换手率为1.31%。近日，公司披露《2026年半年度报告》。总资产为4,809,508,493.04元，较上年度末下降10.64%；归属于上市公司股东的净资产为3,113,463,787.03元，较上年度末下降1.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100031274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","002166","BK0168","BK0028","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048241","title":"莱茵生物（002166）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048241?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:23","pubTimestamp":1788042203,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期莱茵生物发布2026年中报。截至本报告期末，公司营业总收入8.73亿元，同比上升4.35%，归母净利润5654.32万元，同比上升48.37%。按单季度数据看，第二季度营业总收入4.27亿元，同比上升8.62%，第二季度归母净利润1402.66万元，同比上升91.75%。本报告期莱茵生物应收账款上升，应收账款同比增幅达43.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012688","title":"莱茵生物(002166)6月30日股东户数3.7万户，较上期减少5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012688","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012688?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:13","pubTimestamp":1787994817,"startTime":"0","endTime":"0","summary":"证券之星消息，近日莱茵生物披露，截至2026年6月30日公司股东户数为3.7万户，较3月31日减少2013.0户，减幅为5.16%。在化学制品行业个股中，莱茵生物股东户数高于行业平均水平，截至6月30日，化学制品行业平均股东户数为3.1万户。从股价来看，2026年3月31日至2026年6月30日，莱茵生物区间跌幅为31.87%，在此期间股东户数减少2013.0户，减幅为5.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","BK0174","BK0046","BK0028","BK0239","BK0168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663187710","title":"图解莱茵生物中报：第二季度单季净利润同比增长91.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663187710","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663187710?lang=zh_cn&edition=full","pubTime":"2026-08-29 02:55","pubTimestamp":1787943337,"startTime":"0","endTime":"0","summary":"证券之星消息，莱茵生物2026年中报显示，上半年度公司主营收入8.73亿元，同比上升4.35%；归母净利润5654.32万元，同比上升48.37%；扣非净利润4519.16万元，同比上升34.13%；其中2026年第二季度，公司单季度主营收入4.27亿元，同比上升8.62%；单季度归母净利润1402.66万元，同比上升91.75%；单季度扣非净利润486.35万元，同比上升299.16%；负债率33.5%，投资收益224.67万元，财务费用2275.7万元，毛利率24.79%。财报数据概要请见下图:本文数据来源于莱茵生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658861059","title":"莱茵生物董秘罗华阳荣获第十二届金麒麟·金牌董秘荣誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2658861059","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658861059?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:53","pubTimestamp":1786348380,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索查看更多考评等级专题：专题：第十二届金麒麟·金牌董秘及优秀证代荣誉榜单揭晓！8月10日，新浪财经第十二届金麒麟金牌董秘榜单正式揭晓。莱茵生物（维权）董事会秘书罗华阳凭借扎实的合规治理能力、成熟的投资者关系运营、长期稳健的资本价值传递表现，荣耀加冕第十二届金麒麟金牌董秘。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-08-10/doc-inimvnpm2803518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0028","BK0239","BK0174","BK0168","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343312","title":"股市必读：莱茵生物（002166）7月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343312?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:35","pubTimestamp":1785695713,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，莱茵生物报收于6.65元，上涨2.15%，换手率1.65%，成交量12.19万手，成交额8032.81万元。董秘最新回复投资者： 莱茵生物深耕天然健康成分与合成生物学，十五五疾病规划中关于“慢性病防治”与“全民健康”的导向，将为贵公司带来业务机遇？但政策导向不代表业绩必然兑现，业务发展还受市场竞争、客户拓展等多重因素影响。当日关注点交易信息汇总：7月31日主力资金净流入264.96万元，占总成交额3.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0168","002166","BK0028","BK0239","BK0174"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653713119","title":"莱茵生物：与海内外众多品牌客户建立稳定合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653713119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653713119?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:44","pubTimestamp":1784778296,"startTime":"0","endTime":"0","summary":"贵司作为天然甜味剂提取的龙头企业，贵司的产品质量受到众多国内外客户的高度评价和认可，这是可喜可贺的事情。贵司产品通过国内外众多头部品牌企业的率先采用，带动了其他品牌客户的需求，这种销售策略也值得赞扬。近年来公司持续发力开拓下游应用市场，与海内外众多品牌客户建立稳定合作，覆盖食品、饮料、化妆品、医药等赛道，同时在调味品、宠物及动物等新领域的拓展也收获阶段性成效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300020096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","BK0239","BK0046","BK0028","BK0168","BK0174"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793553868454,"stockEarnings":[{"period":"1week","weight":-0.0851},{"period":"1month","weight":-0.1309},{"period":"3month","weight":-0.1113},{"period":"6month","weight":-0.3196},{"period":"1year","weight":-0.2332},{"period":"ytd","weight":-0.2931}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"桂林莱茵生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41528人(较上一季度增加12.15%)","perCapita":"17784股","listingDate":"2007-09-13","address":"广西壮族自治区桂林市临桂区人民南路19号","registeredCapital":"74160万元","survey":" 桂林莱茵生物科技股份有限公司的主营业务是天然健康功能性成分的研发与生产。公司的主要产品是罗汉果提取物、甜叶菊提取物、茶叶提取物及其他植物提取物、甜菊糖苷RM系列产品、左旋β-半乳葡聚糖。","listedPrice":9.89},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱茵生物(002166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱茵生物(002166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱茵生物,002166,莱茵生物股票,莱茵生物股票老虎,莱茵生物股票老虎国际,莱茵生物行情,莱茵生物股票行情,莱茵生物股价,莱茵生物股市,莱茵生物股票价格,莱茵生物股票交易,莱茵生物股票购买,莱茵生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱茵生物(002166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱茵生物(002166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}